Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Fanconi Anemia 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × SRA737 × Sarcoma × Clear all
NCT02797977 2023-06-22

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Sierra Oncology LLC - a GSK company

Phase 1/2 Completed
153 enrolled
Classical hematologySarcomaThoracic

Fanconi Anemia, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡